Prospective study of efficacy and safety of transcatheter arterial chemoembolization (TACE) with miriplatin for hepatocellular carcinoma.
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000005995
- Lead Sponsor
- Kyoto Prefectural University of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Refractory pleural effusion or ascites 2) Encephalopathy 3) Concurrent disease a) Serious hypertension b) Severe heart disease c) Acute myocardial infarction within 6 months prior to inclusion d) Active double cancer e) Severe mental disorder f) Allergic reaction to iodine contrast material g) Severe drug allergy 4) Intrahepatic or portal-caval shunts 5) Tumor thrombosis in main portal vein or vena cava 6) Pregnant and lactating females; females of childbearing age unless using effective contraception 7) Patients who are concluded to be inappropriate to participate in this study by their physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall survival, Child-Pugh status progression
- Secondary Outcome Measures
Name Time Method Progression free survival, Tumor response, Safety